The Department of Health and Human Services (HHS) suggested the DEA reclassify cannabis as a Schedule III controlled substance under federal law. Assistant Secretary for Health Rachel Levine's letter triggered a much-needed rally in cannabis stocks.

In a recent analyst note, a leading cannabis equity research firm, Zuanic & Associates (Z&A), delved into potential scenarios, after the transcended events. 

Seeking clarity, cannabis investors are invited to meet Pablo Zuanic, chief analyst at Z&A, at the Benzinga Cannabis Capital Conference in Chicago, September 27-28. Engage in conversations about the potential scenarios in the U.S. cannabis market and gain invaluable insights from a prominent industry analyst.

Options And Best-Case Scenarios

AdviserShares Pure US Cannabis ETF (ARCA: MSOS) and the ETFMG Alternative Harvest ETF (ARCA: MJUS) surged, accompanied by prominent companies such as Canopy Growth Corporation (NASDAQ: CGC), Curaleaf Holdings, Inc. (OTC: CURLF), Tilray, Inc. (NASDAQ: TLRY), Cresco Labs, Inc. (OTC: CRLBF), Green Thumb Industries Inc. (OTC: GTBIF), and Trulieve Cannabis Corp. (OTC: TCNNF).

Pablo Zuanic, Z&A's chief analyst, outlines three plausible scenarios for the future of the cannabis market in light of the HHS's reclassification recommendation.

These scenarios encompass moving medical cannabis to Schedule III, potentially enabling it to be federally approved as a pharmaceutical product, while maintaining …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.